WO2022015251A1

WO2022015251A1 - A detection device and method for respiratory viruses

Info

Publication number: WO2022015251A1
Application number: PCT/TR2020/050623
Authority: WO
Inventors: Hatice TURHAN; Reyhan KUCUKKAYA; Ovunc YAZGAN; Sule BASARSLAN; Arif Atahan CAGATAY; Veysel Sabri HANCER
Original assignee: Microne Saglik Ve Bilisim Teknolojileri A.S.
Priority date: 2020-07-13
Filing date: 2020-07-13
Publication date: 2022-01-20

Abstract

The invention relates to a detection device that comprises a housing (20), a slot (22) provided on the housing (20) into which a container (40) can be removably disposed, in which a mixture of biological material taken up containing an organic material degrading buffer fluid (3) and a marker (4) preferably selected as fluorescent is provided, and particle manipulator (60) in which the marker (4) is applied to the biomolecules exposed by the buffer liquid (3) in the container (40), and provided adjacent the slot (22) to direct the electrically charged target molecules (5) towards a predetermined deposition zone (z) within its domain, and its relevant method thereof. Detection device comprises a container (40) provided with a mixture containing a fluorescent marker (4) with an oligonucleotide sequence that is 50% identical to at least one of the genomic DNA/RNA, DNA or RNA sequence SEQID NO:1, SEQID NO:2, and SEQID no:3, and at least one lens (52) that is visually accessible from a front portion of the slot (22) towards the deposition zone (z) and with an adjusted focal length (f) to optically enlarge the focusing zone with respect to the deposition zone (z).

Description

A DETECTION DEVICE AND METHOD FOR RESPIRATORY VIRUSES

TECHNICAL FIELD

The present invention particularly relates to a device that detects viruses such as influenza flu that cause infectious diseases affecting the upper respiratory tract and, in progressive cases, the lower respiratory tract, and the relevant method thereof.

The present invention particularly relates to a device that enables the detection of viruses that cause the SARS-CoV-2, which is called the corona virus due to its crown-like structure, as defined in the art, and diseases showing symptoms such as covid-19, and similar and derivatives of this virus.

STATE OF THE ART

Today, infectious diseases are one of the three most important health problems that threaten human life, along with cardiovascular diseases and the types of cancer. Early diagnosis of the causative agent (bacteria, virus, fungus) of the infectious disease is an important factor that determines the success of treatment. In the conventional diagnosis of the infectious agent, it is essential to examine the samples (biological materials) taken from the relevant region (mouth, throat, tonsils, sputum, related area). Molecules in living beings are called biological materials or biomolecules. If the biological materials (biomolecules) in the sample are bacteria or fungi, they are cultivated in a particular medium, and pathogenic bacteria are produced and a relevant diagnosis is tried thereof. With this method, it is possible to produce less than 2% of the bacteria in nature, and the process requires 16-24 hours. Bacterial and fungal cultures are examined in private laboratories by expert microbiologists. The identification of virus genetic material (nucleic acids, DNA or RNA) is used in the diagnosis of viruses. For this process, the nucleic acid of the virus must be isolated from the infected biological material, and the nucleic acid must be amplified (amplified) by polymerase chain reaction (PCR) and visualised in some way. Specially equipped laboratories and molecular biology experts are required in this process. Experts conduct their work with expensive devices and consumables. Since such laboratories cannot be found in every health institution, samples are usually collected in certain centers, and it is aimed to carry out tests after a certain number of samples is reached due to their costs. Isolation and PCR amplification takes approximately 3-4 hours. This process can take up to 6- 24 hours when additional procedures are required such as sample collection and transfer of these samples to another center. In patent application numbered W02004111274A1 , the nucleic acid sequences that can be used in the diagnosis of viruses relate more specifically to the diagnosis of infections with a novel human coronavirus causing Severe Acute Respiratory Syndrome (SARS). The present invention provides nucleotide sequences that can be used as primers and probes in the amplification and detection of SARS nucleic acid. The oligonucleotide sequences provided in this application are disclosed in the nucleocapsid gene, in the replicase gene of the SARS Coronavirus genome. It is disclosed that a sensitive and specific detection of SARS Coronavirus can be obtained via using the sequences according to the present invention in established methods for amplification and detection of nucleic acid. It is stated that oligonucleotide sequences according to the present invention can be used in methods for amplification of nucleic acid.

There is a need for studies on the development of screening tests that will be able to identify the target pathogen easily, quickly, reliably and inexpensively especially in diseases affecting the respiratory tract, without the need for amplification methods from biological materials such as mucus, epithelial cells, saliva obtained from the relevant region (mouth, throat, tonsil, sputum region, aspiration method and region, etc.) in the conventional diagnosis of the infectious agent, and that can be used by everyone and will not require special laboratory personnel or equipment. As the most important problem of the current detection kits is that virus detection needs long periods. There are thousands of commercial products that are effective directly and indirectly in the related technical field for pathogen detection. Furthermore, there is a need for adaptation studies to be applied for the SARS-CoV-2 virus, affecting the certain parts of the world or the whole world enough to be acknowledged as an epidemic or pandemic, and to be made specific to these viruses.

Immediate detection of infected people is of vital importance in regards to epidemics where large numbers of people are affected, as in the COVID-19 pandemic. Testing 20,000-50,000 people a day outperforms the capacities of the laboratories that can perform this process, and the cost is considerably high and the validation period is prolonged. The World Health Organization estimates that the COVID-19 pandemic will continue its existence until 60% of the world's population is infected with this virus. COVID-19 drifted the whole world into a state of chaos; together with the human deaths and economic losses caused by the old pandemics caused by influenza and similar microbes in the historical process, it has shown how important immediate pathogen screening tests are in the control of the epidemic. In environments such as health institutions, factories, schools; medical screening of individuals for pathogens that cause the epidemics at city and country borders and customs is becoming routine procedures. Therefore, there is a need to develop screening tests that can easily, quickly, reliably and cheaply recognize the targeted corona virus from biological materials, that can be used by everyone and that do not require special laboratory personnel or equipment. A test method and apparatus that does not require variable expert interpretation for the detection of SARS- CoV-2 virus and its derivatives and diseases such as the current pandemic covid-19, etc., without requiring long periods, without exposing the relevant disease while detecting, and with advantageous costs compared to expensive equipment and test instruments.

BRIEF DESCRIPTION OF THE INVENTION

The object of the invention is to detect respiratory system viruses such as SARS-CoV-2, influenza, rhinovirus, Coronavirus, RSV, adenovirus, influenza, parainfluenza, etc. and their derivatives by focusing process that utilizes zeta potential or electrical charges, and to facilitate the monitoring process.

Another object of the invention is to provide a product with a cost advantage over existing laboratory and test devices for the detection of biomolecules, such as genetic material, of the factors causing infectious diseases caused by respiratory system viruses and their derivatives such as SARS-CoV-2, influenza, etc. Another aim of the present invention is to provide a test method and a device for the detection of the genetic material of the virus causing the infectious diseases caused by viruses affecting the respiratory system and their derivatives such as SARS-CoV-2, influenza etc.

In order to achieve the abovementioned objects, the invention is a detection device comprising a detachable housing with a container provided on the enclosure, in which a mixture (substrate) containing an organic material-degrading buffer and a marker with a respiratory-acting virus binding oligonucleotide sequence can be removably disposed and a particle manipulator provided adjacent to the housing in such a way that biomolecules exposed by the buffer fluid in the container combine with the marker and direct the electrically charged target molecules towards a predetermined deposition site within the range of action, wherein a container provided with a mixture, preferably containing a fluorescent marker, having an oligonucleotide sequence 50% identical to at least one of the genomic DNA/RNA sequence SEQID NO:1 , SEQID NO:2 and SEQID no:3, and at least one lens arranged visually accessible from a front part of the housing towards the deposition zone, and a focal length adjusted to optically enlarge the focusing zone with respect to the deposition zone thereof. Thus, the target molecule and the biomolecule to be detected are made visually accessible.

Aforementioned biomolecule comprises respiratory system viruses and derivative microorganisms. Thus, the device with the appropriate container selected to contain the fluorescent dye-labeled oligonucleotide that binds to the suspected virus acting on the respiratory tract capable of causing disease will detect the presence of the suspected virus in the sample taken from the patient.

In another embodiment of the invention, relevant device comprises a marker with an oligonucleotide sequence that binds to the virus with a genomic dna/rna sequence of 60%, 70%, 80%, 90%, or 100% identical to at least one of SEQID NO:1 , SEQID NO:2, and SEQID #3. In another embodiment of the invention, the marker is preferably selected as a fluorescent dye and/or the genomic DNA RNA sequence of the fluorescent marker is preferably 80% or 90% identical to at least one of SEQID NO:1 , SEQID NO:2 and SEQID no:3. Therefore, known viruses and their derivatives consisting of mutations can be detected. The sequence listings here provide mostly unchanged DNA sequences of known respiratory viruses. RNA sequences are also formed when a uracil (U) binds to the thymine (T) in the sequence. In the embodiment according to the invention, the oligonucleotide sequence is linked regardless of being a T instead of 'Ll'. Vice versa, it connects with 'Ll' instead of 'T'.

In another embodiment of the invention, the mentioned device comprises a container that is preferably 80% or 90% identical to at least one of the genomic DNA RNA sequence SEQID NO:1 , SEQID NO:2 and SEQID no:3 simultaneously in the container chamber to detect the presence of at least two respiratory viruses, and in which oligonucleotide sequences are applied with at least two different markers selected from fluorescent dyes that bind to one or more respiratory viruses. Thus, the presence of viruses affecting the respiratory system in patients who have been exposed to viruses that are relevant to more than one respiratory system disease will be able to be detected with the help of a single container at the same time. In a preferred application of the invention, two respiratory system viruses, such as SARS-CoV- 2 virus that is present in the same sample or that is effective, and an influenza virus such as H1 N1 or H5N1 , will be detected simultaneously in the same sample taken from the patient with suspected disease. In another preferred embodiment of the invention, it will be determined whether the existing or active SARS-CoV-2 virus, H1 N1 virus and H5N1 virus coexist or are effective in the sample of the same swab taken with the aim of detecting three respiratory system viruses. In a preferred embodiment of the invention, the selected oligonucleotides are adjusted to prevent the respiratory viruses of the invention from binding to different organisms. Thus, detection of the virus is ensured without binding to other organisms and transforming into high-numbered primary structures.

A preferred embodiment of the invention operates on both patient samples and microorganisms. Respiratory tract viruses can be detected in respiratory tract samples in different ways such as nasal swab, bronchoalveolar lavage fluid, bronchoalveolar fluid.

The device of a preferred embodiment of the invention can be used for diagnostic purposes, in the diagnosis of viral infections, particularly RNA or DNA, RNA viruses at the molecular level. With this method, it is possible to detect viruses in different patient samples.

For follow-up purposes, mutations detected or found de novo in different samples (nasal swab, oropharyngeal swab, bronchoalveolar lavage fluid, bronchoalveolar fluid, tears) taken from patients known to be in the viremic phase of virus infections will be detected quickly.

In a preferred embodiment of the invention, aforementioned detection device comprises an image sensor disposed on the back of the lens in such a way that the image is focused thereof. Thus, the visual accessibility of the biomolecule or target molecule will be increased.

In a preferred embodiment of the invention, aforementioned detection device comprises a magnet disposed facing the focusing region of said particle manipulator. Thus, the orientation of the charged particles is ensured.

In a preferred embodiment of the invention, relevant detection device comprises a toroidal magnet aligned to the central focusing region of the magnet. This provides guidance for loaded and already loaded parts and biological materials.

In a preferred embodiment of the invention, relevant detection device is located on a concentration axis of a focus of the lens passing through the toroidal center of the magnet.

In a preferred embodiment of the invention, relevant detection device includes a lighting element disposed in the housing in a way that illuminates the housing.

In a preferred embodiment of the invention, relevant detection device comprises a lighting element and preferably, LED at a wavelength suitable for the visibility of the marker to irradiate the biomolecule associated with the predetermined oligonucleotide sequence of the illuminating element. Thus, visual accessibility of the target molecule formed by a marker with the appropriate oligonucleotide sequence is provided. In a preferred application of the invention, the lighting element is selected as a part of the device or as a device or system consisting of more than one part.

In a preferred embodiment of the invention, aforementioned detection device comprises at least one heating element provided inside or outside the chamber.

Thus, the temperature of the chamber is adjusted to predetermined values. In another exemplary embodiment of the invention, the device may not include a heating element.

In a preferred embodiment of the invention, said detection device comprises at least one heating element adapted to the housing so as to catalyze the binding of the marker with the oligonucleotide sequence stored in the container when disposed in the housing, to a catalysis temperature that increases the rate of degradation and/or binding. Thus, the separation of the biomolecule into its genetic materials is provided at predetermined temperature values.

In a preferred embodiment of the invention, a container for said detection device is a chamber filled with a mixture of lysis buffer and a marker with the appropriate oligonucleotide sequence; and the relevant device comprises a retaining wall arranged at least partially transparent to the chamber so that it is visually accessible from the outside, and which, when disposed in the slot, is aligned with the lens. Thus, a container detachable from the slot is provided. Therefore, with the device according to the invention, tests are provided in such a way that a sample of the target molecule of the virus sought in the respiratory system is contained in the chamber as the control group. At least one virus or more than one virus can be detected simultaneously in the container according to the invention. A separate container aligned for each virus will be provided in the device for detection of other viruses.

In a preferred embodiment of the invention, a container for the aforementioned detection device comprises a heat-permeable wall of the chamber that is heat-conductingly engaged with a heating element provided in the slot. Thus, the temperature settings of the container in the slot are provided via heat conduction.

In a preferred embodiment of the invention, a container for the aforementioned detection device comprises at least one heating element provided on the inside or outside of at least one of the inlet wall of the chamber, the detection wall, the second wall and the heat-permeable wall.

In a preferred embodiment of the invention, a container for the aforementioned detection device comprises an extensible sealed inlet that allows the entrance of a carrier head containing the target molecule into the chamber from the back of an outward facing inlet wall when the cartridge is disposed in the slot. Therefore, when the sample is disposed, liquid and sample leakage is prevented.

In a preferred embodiment of the invention, the aforementioned marker is a dye that enhances the visibility of the oligonucleotide in a container of the detection device. In this way, the dye provided in the chamber binds with the appropriate nucleotide and provides marking thereof.

In a preferred embodiment of the invention, a container for the aforementioned detection device is especially selected from the group consisting of sybr safe, sybr green, eva green, Thiazole Green, Ethidium Bromide, Propidium Iodide, dUTP-conjugated Probes, DAPI (4',6- diamidino-2-phenylindole), 7-AAD (7-aminoactinomycin D), Hoechst 33258 ( 33342, 34580), YOYO-1 /DiYO-1/TOTO-1/DiTO-1 flourescent dyes. In another embodiment of the invention, fluorescent dyes with different chemical content, colors, excitation wavelength and physical properties are selected. In another embodiment of the invention, fluorescent dyes with different chemical content, colors, excitation wavelength and physical properties are selected.

In a preferred embodiment of the invention, the relevant detection method comprises process step of filling a mixture of lysis buffer and marker with the appropriate oligonucleotide sequence into the sealed chamber, wherein it also comprises the following process steps: receiving a sample carrier on which the target molecule will be examined from the inlet reaching the chamber; exposing the buffer fluid to the sample carrier to release the genetic material; heating the substrate with the heating element, thereby increasing the rate of release time of the genetic material; entrainment of the charged target molecule in the deposition site with the particle manipulator by matching the released genetic material with the marker with the appropriate oligonucleotide sequence; irradiation with the lighting element to reach the target molecule in the chamber and optical magnification of the radiation scattered from the target molecule by the lens whose focus is aligned to the deposition zone. Thus, visual accessibility of the target molecule is ensured.

In a preferred application of the invention, the mentioned detection method includes the process step of selecting the said marker as a dye, especially as a fluorescent dye, that increases its visibility. Thus, a marking method is provided in a way that the fluorescent dye provided in the chamber radiates by binding the appropriate nucleotides. In a preferred application of the invention, the mentioned detection method includes the process step of placing the lighting element in the said chamber so as to prevent the illumination. Thus, the accessibility of at least one marker with the oligonucleotide sequence provided in the cartridge is ensured.

In a preferred application of the invention, the mentioned detection method includes the process step of digitizing the reflection magnified from the lens by falling on an image sensor and transferring the digital image to a display with the help of a controller. Thus, the digital accessibility of the observed image will be ensured.

Detection device according to the invention will be used for the abovementioned virus examples regarding the respiratory system within the scope of the invention, and similarly for viruses and their derivatives that infect the lower respiratory tract in the respiratory system, starting first in the upper respiratory tract and progressively infecting the lower respiratory tract.

The detection method, as mentioned above, has different options; wherein it sets forth the presence of nucleic acids with sequence and sequence known in the medium. In this regard, the sequence in the target DNA or RNA and the oligonucleotide to bind with nucleotides complementary to the sequence are designed. In this method, dye can be bound to oligonucleotides as well as specific nucleotide sequences (probes) to segments/sections. During the reaction, the energy loading of the ground carrying the test medium and the differences in the absorption and emission values of the light are measured. There is no amplification step in the direct detection method, therefore, a magnetic field is used to concentrate the least detectable amount in the medium.

The target DNA/RNA, DNA or RNA in the target molecule binds to these particles in the liquid medium by coating complementary sequences to the target nucleotide sequences on the magnet pieces. Double-strand can be made visible by the application of a dye that can bind to DNA. Nucleotide size can vary. The dye and LED used may vary. The temperature value of the Lysis (Lysis) fluid selected as the buffer fluid can be changed by adjusting, and spheric lens, aspheric lens, convex lens can be used instead of ball lens. Focal length and radius values can be changed instead of using 1-2mm diameter. It is optional to use a duct or a tapered duct. The optical design sequence may vary such as LED, lens, material. LED band of 480nm-520nm can be expanded for illumination. Emission values of the material to be displayed can be increased in the range of 520-540nm. Alternatively, filter paper (not shown) can be inserted. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is the schematic side-section view of a preferred embodiment of the detection device according to the invention.

Figure 2 is the perspective schematic view of a preferred embodiment of the detection device according to the invention, before inserting the biological kit in the said container into its housing.

DETAILED DESCRIPTION OF THE INVENTION

In this detailed description, the development according to the invention is explained without any limitation and only with references to better explain the inventive subject.

Figure 1 is a schematic cross-sectional illustration of a preferred embodiment of a detection device according to the invention. Detection device according to the present invention includes a housing (20) comprising a slot (22) into which at least one replaceable container (40) can be inserted. Preferably at least one adjustment unit (2) is integrated on the housing (20) in the form of a button protrusion on its upper part.

In another embodiment, the detection device contains more than one knob or a button for a different number of parameters or in the form of a rotary knob. A display (1) is disposed in a desired section on the housing (20), preferably at the top. The housing (20) includes a controller (10) that manages the operation of the fastening device. In an embodiment of the invention, a simple device without controller (10) function can be obtained. The controller (10) preferably includes a processor (12) associated with both the adjustment unit (2) and the display (1). The processor (12) is connected to the display (1 ) and the adjustment unit (2) by means of a cable (not shown) that transmits electrical signals.

A slot (22) is formed on the housing (20). The slot (22) includes an outward opening (21). The housing (20) includes a heating element (25) preferably located at the rear of the slot (22). The shaking process of the device according to the invention is performed manually. In an alternative embodiment of the invention, the container (40) can be triggered to be agitated in a different unit. A container (40) removably disposed and provided with a mixture containing an organic material-degrading buffer liquid (3) and a marker (4) with the appropriate oligonucleotide sequence, preferably selected as a fluorescent dye, which is heated to provide an accelerating effect, is disposed in the slot (22). In another embodiment of the invention, a fluorescent marker (4), for example a red, blue colored dye that can be seen with a white LED, with the appropriate oligonucleotide sequence is selected.

An optical detection unit (50) is located with the help of a channel (54) at the bottom of the container (40) in the detection device according to the invention. A lens (52) is located in the channel (54) in the direction of an accumulation axis (y) that extends perpendicularly to a focal length (f) determined to a focus. The lens (52) is preferably spherical. In an exemplary embodiment, total length is in the range of 1 to 2 mm. In a preferred embodiment of the invention, the lens (52) displays molecules with emission wavelengths of 515-525 nm. The optical detection unit (50) comprises an image sensor (56) located at the bottom of the channel (54) and in the direction of the accumulation axis (y) by transmitting the rays that the lens (52) receives from an deposition zone (z).

The detection device includes a particle manipulator (60) disposed around the channel (54) . The particle manipulator (60) is a disc-shaped magnet (62) with at least one aperture in the middle, preferably positioned to guide a target molecule (5) to the deposition site. A toroidal magnet (62) is preferred. In another embodiment, the particle manipulator (60) includes at least two magnets (62) facing the deposition zone.

The housing (20) includes a lighting element (80) arranged to illuminate the slot (22) over the window (26). A light source with an excitation wavelength of 495-505 nm with a homogeneous and gaussian distribution is preferably used as the lighting element (80). The optical detection unit (50) and the lighting element (80) are connected to the processor (12) by means of a cable (not shown) that provides electrical signal transmission. The container (40) within the detection device includes an inlet (41 ) that can be opened and closed on an inlet wall (42) that can be on any side of its peripheral surface. The inlet (41) can be opened and closed to a height, allowing the sample carrier (30) comprising a carrier cap (34) and a rod (32) to pass. In an embodiment of the present invention, the sample carrier (30) is screwed to the container (40) by means of threads containing the screw path. The inlet (41 ) is designed to be sealed for safety. The container (40) comprises a detection wall (43) in its front part (47), a second wall (45) on the surface of the rear part (48) corresponding to the detection wall (43) and a heat- permeable wall (46) on one side of it. The detection wall (43) becomes aligned with the lens (52) when the container (40) is disposed in the slot (22). Therefore, the detection wall (43) is made of a transparent material with light transmittance. The heat-permeable wall (46) is made of a conductive material in a way that transmits the heat energy provided by the heating element (25).

The container (40) comprises preferably a transparent detection wall (43) on the front part (47), and a chamber (44) at its rear (48) preferably a transparent second wall (45) and delimited by the heat-permeable wall (46) and filled with a mixture of degrading buffer liquid (3) and at least one marker (4) having the appropriate oligonucleotide sequence.

The container (40) comprises an inlet wall (42) with an inlet (41 ) that allows the passing of sample carrier (30) on either side.

With the operating method of the detection device, at least one target molecule (5) is detected. In alternative embodiments of the invention, more than one target molecule (5) can be detected simultaneously for multiple biomolecule detection and, for example, a second target molecule (6) labeled with a fleurescent marker (4) with different oligonucleotide sequences can be detected. For target molecule (5) detection, a mixture of degrading buffer liquid (3) and marker (4) with the appropriate oligonucleotide sequence is filled into the chamber (44) inside the sealed container (40). The oligonucleotide sequence may vary based on the detected molecules. For example, a different oligonucleotide sequence is preferred for influenza- causing viruses such as H1 N1 , H5N1 , or a different oligonucleotide sequence for SARS-CoV- 2 virus. In alternative embodiments of the invention, oligonucleotide sequences suitable for their genome structures can also be used in the aforementioned container (40) to detect viruses that affect different respiratory systems.

The target molecule (5) to be detected is disposed in the carrier cap (34) located on the sample carrier (30). Samples taken from the patient are used for target molecule (5) detection. Sample regions where respiratory system viruses are effective, such as throat swab, are preferred for sampling. The carrier cap (34) containing the sample is immersed in the chamber (44) through the inlet (41) located on the outward side of the container (40). The inlet (41 ) part can be adjusted along the height of the carrier cap (34). After the carrier cap (34) enters into the chamber (44), the inlet (41 ) is mounted preferably by screw rotation, ensuring locking and sealing thereof. After the sample is taken into the chamber (44), it is ensured that the sample is separated to its genetic materials with the help of the buffer liquid (3). Sample is shaken for 5 to 10 minutes depending on the type of target molecule (5) after being taken into the chamber (44) Lysis liquid is preferred as buffer liquid (3). The lysis fluid contains 0.5% (w/v) sodium dodecyl sulfate 0.05 M tris-CI 1 mM dithiothreitol (DTT), providing fat and protein denaturation thereof. Released genetic material is matched to the appropriate oligonucleotide sequence. A bonded structure is obtained by coupling. After coupling, the target molecule (5) is heated by the heating element (25) so as to provide fluorescent staining. Sybr safe, sybr green, eva green, Thiazole Green, Ethidium Bromide, Propidium Iodide, dUTP-conjugated Probes, DAPI (4',6-diamidino-2-phenylindole), 7-AAD (7-aminoactinomycin D), Hoechst 33258 (33342, 34580), YOYO-1/DiYO-1/TOTO-1/DiTO-1 may be preferred as fluorescent dyes.

Fluorescent dye radiates due to its double helix structure. The heating element (25) continues to operate until the average temperature inside the chamber (44) reaches, for example, to 50°C to 90°C, depending on the type of target molecule (5).

After heating process, the target molecule (5) is dragged along the deposition zone (z) by the particle manipulator (60). The target molecule (5) is dragged through the liquid by the electropheresis method, that is, by the use of electrical field with the attraction of the electrical charges on the target molecule (5). The lighting element (80) irradiates the chamber (44) so that it reaches the target molecule (5) and optically magnifies the radiation scattered from the target molecule (5) by a lens (52) aligned with the focal (f) deposition zone (z). The lighting element (80) projects an LED light in line with the excitation and emission values of the preferred dye. The fluorescent dye and the type of LED used must be compatible. The image magnified with the lens (52) is projected onto the image sensor (56) and digitized thereof. In a preferred application of the invention, the digitized image is transferred onto the display (1 ) with the help of the controller (10).

The detection device can test more than a single target molecule (5) to detect the biomolecules of the organism that causes more than one disease at the same time. A mixture of lysis buffer liquid (3) and the marker (4) with the appropriate oligonucleotide sequence is filled into the chamber (44) in the sealed container (40) for detection of the target molecule (5) and the second target molecule (6). Following the transfer of samples from the patient of the determined second target molecule (6) to the the carrier cap (34), a second fleurescent marker (4) is disposed in the chamber (44) together with the fleurescent marker (4) that will detect the target molecule (5), for a predetermined disease detection and in accordance with the second target molecule (6) to radiate at a different wavelength. After relevant mixture is transferred to the chamber (44), the preferred container (40) is preferably increased to the predetermined temperature value with the connected heating element (25) and samples are separated up to their genetic materials together with the help of buffer liquid (3). Performed heating is optional, and appropriate heating accelerates the decomposition of the biological material, the staining of the marker (4) and the adhesion of the dyed or undyed marker (4) to the target molecule. Target molecules (5, 6) form a double helix structure with the fleurescent marker (4) containing the appropriate oligonucleotide sequences. Heating process of the heating element (25) is preferably terminated with the controller (10) when it reaches the target temperature and provides a helical structure in the target molecule (5) and the second target molecule (6), providing fluorescent staining thereof. After heating, the target molecule (5) and/or the second target molecule (6) in the container (40) disposed in the slot (22) is dragged along the deposition zone (z) by the particle manipulator (60).

In an embodiment of the invention, the particle manipulator (60) can only direct a single target molecule (5) as the mixture containing only one target molecule (5) is used in the container (40). In one embodiment of the invention, the device is irradiated with at least one lighting element (80) that radiates at a wavelength suitable for at least one target molecule (5), and the chamber (44) reaches the target molecule (5) and optically magnifies the scattered radiation from the target molecule (5) of the lens (52) with an aligned focus to the deposition zone (z). In another embodiment of the invention, a target molecule (5,6) group containing at least one target molecule (5) is formed by using an appropriate fleurescent marker (4) for more than one biomolecule active for more than one disease in the mixture in the container (40). Accordingly, in the device according to the invention; the chamber (44) is irradiated with more than one and two different lighting elements (80) adjusted in accordance with the first target molecule (5), the second target molecule (6); wherein it reaches the target molecule (5) and the second target molecule (6). The lens (52) focused on the deposition zone (z) optically magnifies the radiation scattered from the target molecule (5) and the second target molecule (6). The magnified image from the lens (52) is projected onto the image sensor (56) and digitized thereof. In a preferred embodiment of the invention, the digitized image is transferred onto the display (1 ) with the help of the controller (10).

Table 1 provides exemplary application of an active biomolecule for at least one respiratory virus with different parameters hereinbelow. Example given is not limited to the table, as the parameters in the tables may contain different values for different diseases.

Table 2 below provides the preferred parameters of an exemplary application of the causative biomolecule for the simultaneous detection of at least more than one respiratory disease.

Throat/nose swab

Throat/nose swab Throat/nose swab

Lysis fluid Fat and protein Fat and protein Fat and protein denaturation denaturation denaturation

Lysis (lysis) buffer; Lysis (lysis) buffer; Lysis (lysis) buffer;

0.5% (w/v) sodium 0.5% (w/v) sodium 0.5% (w/v) sodium dodecyl sulfate dodecyl sulfate dodecyl sulfate

0.05 M tris-CI 0.05 M tris-CI 0.05 M tris-CI pH 8.0 pH 8.0 pH 8.0

1 mM dithiothreitol 1 mM dithiothreitol 1 mM dithiothreitol (DTT) (DTT) (DTT)

Primary 450 nucleotides 500 nucleotides 500 nucleotides

(oligomer)

Shaking 12 min 12min 12min time

Heating Approximately 65⁰ C. Approximately 65 ⁰ C. Approximately 65 ⁰ C. temperature heating Indirect heater (Gel) Indirect heater (Gel) Indirect heater (Gel) element

Fluorescent Sybr safe sybr red sybr red

Marker light 530nm 400nm 400nm wavelength

Focus toroidal magnet toroidal magnet jtoroidal magnet viewing 2mm optical lens 2mm optical lens |2mm optical lens

Magnificatio 400 x 400 x 400 x n ratio

Interpretatio CCD camera CCD camera CCD camera n

Target Primer - Target Molecule (5) Second Target Third target molecule (7) Virus molecule (6) binding

The rod (32) of the sample carrier (30), where the sample taken from the patient or the microorganism will be disposed, is preferably long enough to enter the throat and nose, especially preferably 7-10 cm, and the tip is covered with liquid absorbent, for example cotton. Throat or nose swab can be taken with the sample carrier (30) with rod (32). In a preferred embodiment of the invention, the sample carrier (30) is disposed in the chamber (44) of the disposable container (40).

The sample carrier (30) is preferably screwed at one end of the rod (32) to provide sealing, and preferably the outside part of the rod (32) is broken. The chamber (44) of the container (40) is shaken gently, preferably for 5-7 minutes. After the shaking process, the chamber (44) of the device is filled and the container (40) comprising the sample carrier (30) is disposed in the housing (20) of the device. The target molecule (5) particles formed in the container (40) inside the device are directed towards the lens (52) of the optical detection unit (50) by the particle manipulator (60). With the lighting element (80), which is a LED light suitable for irradiation, the target molecule (5) particles are provided with fluorescent excitation. The resulting irradiation is observed in the display (1 ), the display screen, via the image sensor (56). Formation of oligomers/ oligonucleotides, preferably between 400 and 500 nucleotides in length will be seen in the examples. Different lengths of nucleotides can be preferred in different embodiments.

For example; in Example 1 given in Table 1 above, H1 N1 was preferred as the target molecule (5) and swab was preferred as the sample. A mixture of lysing buffer (3) and marker (4) with the appropriate oligonucleotide sequence for fungal detection is filled into the chamber (44) inside the sealed container (40). 450 nucleotides compatible for H1 N1 were determined as the oligonucleotide sequence.

Throat/nose swab samples taken from the patient are disposed in the carrier cap (34) and immersed in the chamber (44). After their transfer to the chamber (44), the buffer liquid (3) and preferably a heating element (25) in connection with the cartridge (40) is heated to approximately 65°C. Heating process is ceased after the heating element (25) reaches 65 °C. The samples are preferably separated up to their genetic material by manually shaking. The chamber (44) is preferably shaken for 5 minutes after the relevant mixture is transferred into the chamber (44). SARS-CoV-2 virus forms a double helix structure with suitable oligonucleotide sequences. The target molecule (5) structure is formed in a way that provides fluorescent staining after helix structure. In this example, sybr green was preferred as the dye color. An indirect gel heater is preferred as a heating element (25) in this example. After heating process, the target molecule (5) is dragged along the deposition zone (z) by the particle manipulator (60). The particle manipulator (60) is preferably a toroidal magnet chosen for this example. With the lighting element (80), electrical illumination (electroluminescent) is irradiated with a wavelength of 500 nm so that the chamber (44) reaches the target molecule (5), and the lens (52) with an aligned focus to the deposition zone (z) optically magnifies the scattered radiation from the target molecule (5).

The lens is 2 mm long and the optical magnification is 360 times in this example. The image magnified with the lens (52) is projected onto the image sensor (56) and digitized thereof. The digitized image is transferred to the optical detection unit (50) preferably containing a CCD camera with the aid of the controller (10). The image magnified with the lens (52) is projected onto the optical detection unit (50) and digitized thereof. The digitized image is transferred to the image sensor (56) with the help of the controller (10). In an embodiment of the invention, the image is transferred to a CCD camera with the help of the controller (10).

In example 2 given in table 1 above, a sample selected for the detection of the genetic material of an H1 N1 influenza type virus organism was obtained via aspiration as the target molecule (5). For the detection of the target molecule (5) of the H1 N1 influenza type virus, a mixture of the lysis buffer (3) and the marker (4) with the appropriate oligonucleotide sequence is filled into the chamber (44) in the sealed container (40).

As the oligonucleotide sequence, length of 450 nucleotides was determined, which are preferably compatible with the H1 N1 influenza type virus. Aspiration samples taken from the patient are instilled in the carrier cap (34) and immersed in the chamber (44). After the helix structure, the H1 N1 influenza type virus is heated up to 50 °C by the heating element (25), providing fluorescent staining. After the sample is taken into the chamber (44), it is ensured that the sample is separated to its genetic materials with the help of the buffer liquid (3). The chamber (44) is shaken for 5 minutes after the transfer of the sample. After heating process, the genetic materials of the H1 N1 influenza type virus form a double helix structure with the appropriate oligonucleotide sequences. In this example, sybr safe was preferred as the dye color. An electrical heater is preferred as a heating element (25) in this example.

The target molecule (5) consisting of the genetic material of the H1 N1 influenza type virus is dragged along the deposition zone (z) by the particle manipulator (60). The particle manipulator (60) is preferably a toroidal magnet chosen for this example. With the lighting element (80), the chamber (44) is irradiated with a wavelength of 530 nm, reaching the H1 N1 influenza type virus, and the lens (52) with an aligned focus to the deposition zone (z), optically magnifies the radiation scattered from the H1 N1 influenza type virus. In this example, the lens is 1.5 mm long and the optical magnification is 400 times. The image magnified with the lens (52) is projected onto the image sensor (56) and digitized thereof.

In example 3 given in Table 1 , H5N1 influenza type virus was preferred as the target molecule (5) and the sample was obtained from bronchoalveolar lavage fluid. A mixture of lysing buffer (3) and marker (4) with the appropriate oligonucleotide sequence for H5N1 influenza type virus detection is filled into the chamber (44) inside the sealed container (40). 500 nucleotides compatible with the H5N1 influenza type virus were determined as the oligonucleotide sequence. Urine samples taken from the patient are instilled in the carrier cap (34) and immersed in the chamber (44). The container (40) comprising the H5N1 influenza type virus is preferably heated up to 90 °C by the heating element (25), providing fluorescent staining. The chamber (44) is shaken for 10 minutes after the transfer of the sample. H5N1 influenza type virus forms a double helix structure with suitable oligonucleotide sequences. After the sample is taken into the chamber (44), it is ensured that the sample is separated to its genetic materials with the help of the buffer liquid (3). In this example, sybr red was preferred as the dye color. An induction heater is preferred as a heating element (25) in this example. In the container (40) chamber (44), the marker (4) preferred as the fleurescent dye circulates freely. Likewise, binding and radiation occurs in the case of a suitable match in a single-chain agar in the post virus genetic materials that are separated into parts.

After the helical structure, the target molecule (6) containing the genetic materials of the H5N1 influenza type virus is dragged along the deposition zone (z) by the particle manipulator (60). The particle manipulator (60) is chosen as the electromagnet for this example. The chamber (44) is irradiated via the lighting element (80) with a wavelength of 400 nm, reaching the target molecule (6) of the H5N1 influenza type virus, and the lens (52) with a focus aligned to the deposition zone (z) optically magnifies the irradiation scattered from the target molecule (6) of the H5N1 influenza type virus. In this example, the lens is selected as 2 mm long convex lens and the optical magnification is 400 times. The image magnified with the lens (52) is projected onto the optical detection unit (50) and digitized thereof. The digitized image is transferred to the image sensor (56) with the help of the controller (10). In an embodiment of the invention, the image is transferred to a CCD camera with the help of the controller (10).

For example, in the application given in Table 2 above, SARS-CoV-2 was chosen as the target molecule (5) and H1 N1 as the second target molecule (6) in example 4, and throat / nose swab was preferred as the sample collection mediums. For simultaneous detection of SARS-CoV-2 and H1 N1 viruses, a mixture of the lysis buffer (3) and the marker (4) with the oligonucleotide sequence suitable for SARS-CoV-2 and H1 N1 viruses is filled into the chamber (44) in the sealed container (40). As the oligonucleotide sequence, 450 nucleotides, 500 nucleotides and 500 nucleotides were determined, which were compatible for SARS-CoV-2 and H1 N1 , respectively.

Throat/nose swab samples taken from the patient are disposed in the carrier cap (34) and immersed in the chamber (44). After their transfer to the chamber (44), the buffer liquid (3) and preferably a heating element (25) in connection with the cartridge (40) is heated to approximately 65°C. Heating process is ceased after the heating element (25) reaches 65 °C. The samples are preferably separated up to their genetic material by manually shaking. The chamber (44) is preferably shaken for 5 minutes after the relevant mixture is transferred into the chamber (44). SARS-CoV-2 and H1 N1 viruses form a double helix structure with suitable oligonucleotide sequences. The target molecule (5) structure is formed in a way that provides fluorescent staining after helix structure. In this example, sybr green was preferred as the dye color. An indirect gel heater is preferred as a heating element (25) in this example. After heating process, the target molecule (5) is dragged along the deposition zone (z) by the particle manipulator (60). The particle manipulator (60) is preferably a toroidal magnet chosen for this example. With the lighting element (80), electrical illumination (electroluminescent) is irradiated with a wavelength of 500 nm so that the chamber (44) reaches the target molecule (5), and the lens (52) with an aligned focus to the deposition zone (z) optically magnifies the scattered radiation from the target molecule (5) and the second target molecule (6).

Table 2 provides a device for target primer assembly in an embodiment of the invention preferably comprising a marker (4) with an oligonucleotide sequence suitable for more than two, and in particular, all 3 viruses individually. In example 5 given in the application in table 2, SARS-CoV-2 was preferred as the target molecule (5), H1 N1 as the second target molecule (6), and H5N1 viruses as the third target molecule (7), and throat / nose swab was chosen as the sampling mediums. For simultaneous detection of SARS-CoV-2, H1 N1 and H5N1 viruses, a mixture of the lysis buffer (3) and the marker (4) with the oligonucleotide sequence suitable for SARS-CoV-2, H1 N1 and H5N1 viruses is filled into the chamber (44) in the sealed container (40). As the oligonucleotide sequence, 450 nucleotides, 500 nucleotides and 500 nucleotides were determined, which were compatible for SARS-CoV-2, H1 N1 and H5N1 viruses, respectively.

Throat/nose swab samples taken from the patient are disposed in the carrier cap (34) and immersed in the chamber (44). After their transfer to the chamber (44), the buffer liquid (3) and preferably a heating element (25) in connection with the cartridge (40) is heated to approximately 65°C. Heating process is ceased after the heating element (25) reaches 65 °C. The samples are preferably separated up to their genetic material by manually shaking. The chamber (44) is preferably shaken for 5 minutes after the relevant mixture is transferred into the chamber (44). SARS-CoV-2 virus forms a double helix structure with suitable oligonucleotide sequences. The target molecule (5), the second target molecule (6), and the third target molecule (7) are formed in the presence of viruses, providing fluorescent staining after the helical structure. In this example, sybr green was preferred as the dye color. An indirect gel heater is preferred as a heating element (25) in this example. After heating process, the target molecule (5) is dragged along the deposition zone (z) by the particle manipulator (60). The particle manipulator (60) is preferably a toroidal magnet chosen for this example. With the lighting element (80), electrical illumination (electroluminescent) is irradiated with a wavelength of 500 nm so that the chamber (44) reaches the target molecule (5), and the lens (52) with an aligned focus to the deposition zone (z) optically magnifies the scattered radiation from the target molecule (5) and the second target molecule (6).

In Figure 2, a perspective schematic view of the biological kit prepared with the appropriate oligonucleotide sequence for any of the respiratory system viruses in the said container (40) into the housing of a preferred embodiment of the detection device is given before insertion. A display (1 ) is disposed in a rectangular form on the housing (20) so that the images transferred to the digital can be seen. The display (1) can also be disposed in different geometrical structures, for example in a circular form. At least one adjustment unit (2), which is formed as a projection, is located at the lower part of the display (1 ). One or multiple parameters can be controlled in the adjustment unit (2). Adjusted parameters (such as temperature, wavelength) may increase or decrease in line with predetermined criteria. The space (24) is visibly designed in the form of an open slot entrance in the case where the container (40) is not disposed in the slot (22). A lens (52) is positioned in the lower part of the detection wall (43) preferably in the spherical form. There is at least one magnet (62) or magnets (62) located circularly around the lens (52).

The device according to invention is a rapid scanning kit designed to detect biomolecules of respiratory system viruses such as H1 N1 , H5N1 , SARS-CoV-2 and/or their derivatives found in biological materials. Respiratory system viruses, which are similarly taken from samples not described herein with known dna/rna sequence can also be detected with this device. With this device; biological material aspiration, mouth or throat swab, etc., the genetic material of the microorganism in the container (40) is exposed by a rinsing process with the buffer liquid (3).

In an exemplary application of the invention, lysis buffer is preferred as the aforementioned buffer liquid (3). Primarily, the appropriate marker (4), buffer liquid (3) and the sample carrier (30) taken are disposed in the container (40). In this case, for example, they mark the genetic material of the virus as the target molecule (5) by using a specific oligonucleotide labeled with a fluorescent dye specially designed for the virus RNA as a biomolecule. In another embodiment of the invention, they are also designed specifically for thymine binding DNA instead of uracil in the form of RNA.

In a preferred embodiment of the invention, they also collect the labeled virus RNA into a deposition zone (z) without amplification and without the need to increase illumination with a light source. In an exemplary embodiment of the invention, fluorescence scattering is investigated by using an image processing method and an optical detection unit (50) inside the device. All these processes can be viewed with the help of a lens selected in accordance with the container (40) chamber (44) according to the invention, which can be redisposed and disassembled and the upper and lower parts of the walls forming the chamber (44) are preferably transparent. Thus, in the device according to the invention, the test is completed in about 5-15 minutes and the presence of virus or similar genetic material is detected and identified thereof. Thus, the invention constitutes a rapid diagnosis kit. Usage area of the invention may be for diagnosis and follow-up of treatment. The system of an exemplary device of the invention can be used to directly and quickly identify the virus affecting the respiratory system in any biological material or liquid sample.

RNA DNA (charged particle) separated from the sample dissolved in the lysis liquid at a certain temperature, preferably, and especially in the range of 40-90 °C, and especially preferably at 65 °C is collected at the focal point of at least one special lens (52) according to the invention, which is a particle manipulator (60) tuned through the liquid, preferably with magnet (magnetophoresis), etc. techniques without duplication of genetic material. Thiazole Green, Ethidium Bromide, Propidium Iodide, dUTP-conjugated Probes, DAPI (4’,6-diamidino-2- phenylindole), 7-AAD (7-aminoactinomycin D), Hoechst 33258 (33342, 34580), YOYO- 1/DiYO-1/TOTO-1/DiTO-1 vb.) are used as fluorescent dye used as a suitable lighting element (80) to capture images over the detection wall (43) where the lens (52) container (40) is preferably transparent in alternative embodiments of the invention. An LED (electroluminescent light source) is selected in line with the excitation and emission values of the dye. The sample suspected to contain the microorganism or virus taken from the patient is disposed in the container (40).

Saliva, throat swab, tears, aspiration material from a related tissue, etc. may be the exemplary samples. In this container (40), all biological residues (epithelial cells, virus protein coat, etc.) are decomposed, except for the “lysis” buffer (3) (genetic material- DNA, RNA). When the genetic material is released in the liquid, a double helix structure is obtained by binding with the appropriate aligned oligonucleotide sequence stained with the fleurescent marker (4) at the predetermined appropriate temperature. The marker (4), which is a fluorescent dye, radiates when the target molecule (5) is formed after the occurrence of a double helix. The heating process of the container (40) disposed in the sample carrier (30) can be performed with at least one heating gel, electric current, induction current, etc. preferred as the heating element (25).

The labeled target molecule (5) and/or the second target molecule (6) combined with the targeted genetic material in the free state in the buffer liquid (3) is collected into the focus of the lens with methods of magnetophoresis, electrophoresis, and dielectrophoresis, etc. The particles radiating under the light provided by the appropriate lighting element (80) are observed by processing with the help of the lens (52) of the optical detection unit (50) and the image sensor (56). In a preferred embodiment of the invention, the lighting element (80) is chosen as an element that is a part of the device or as a device or system consisting of more than one part. Observance of the radiation in the system means indicates the fact that the presence of the target molecule (5) is positive. This situation is also interpreted as the detection of the causative agent.

The biological kit in the container (40) contains an oligonucleotide sequence stained with a dye that is a fleurescent marker (4) designed in accordance with the targeted genetic material, and buffer liquid (3), preferably consisting of a "lysis" enzyme that degrades other biological wastes. In the heating system of the invention, at least one heating element (25) is preferred to provide the appropriate temperatures for enzyme activation and/or reaction rate. Preferably, the container (40) is disposed on the inner or outer wall of the chamber (44) preferably on the heat- permeable wall (46) in order to maintain a temperature of 60-70 °C. The particle manipulator (60) of the device according to the invention directs electrically charged genetic material formed by the biomolecule inside the chamber (44) of the container (40) in which the sample carrier (30) is disposed by using magnetic field. The particle manipulator (60) may comprise magnets and materials capable of generating a static/dynamic magnetic field, and such systems. The optical detection unit (50) of the device according to the invention comprises at least one lens (52), the channel (54) comprising the imaging lens, at least one filtering element (not shown), the lighting element (80) in contact with the lens (52) at an appropriate predetermined angle, and the image sensor (56).

The optical detection unit (50) preferably includes a ball lens. The optical detection unit (50) also preferably includes a funnel (54) for efficient observation of the genetic material of the biomolecule (DNA, RNA...) to be imaged. The unit is connected with the LED lighting element (80) that provides appropriate radiation to the optical detection unit (50). The unit has the capacity to display cells with emission wavelengths of 515-525nm, therefore, a spherical lens, preferably in the 1-2mm diameter range, is used. The channel (54) used herein, and preferably its narrowing structure, will ensure that the light emitted from the LED lighting element (80) is collected and reduced to the target molecule (5) that has the genetic material in the chamber (44). Thus, images perceived from the light will be transferred directly to the spherical lens (52), and the number of photons per unit area in the image falling on the detector of the image sensor (56) will be increased.

Preferably a homogeneous and Gaussian distribution light source with an excitation wavelength of 495-505nm will be used as the lighting element (80). In an alternative embodiment of the invention, the device includes a filtering element between the optical detection unit (50) and the lighting element (80), absorbing the light and creating a dark spot thereof. The optical detection unit (50) of this device will preferably ensure that the analogous image, that is, the photons sent by collecting with the spherical lens (52), is converted into a digital image, preferably with the selected image sensor (56) such as CCD, etc. In a preferred embodiment of the invention, morphological processing will be performed by calculating the histogram values of the images obtained from the magnification in the optical detection unit (50). For example, images with a wavelength of 515-525nm will be labeled and counted. REFERENCE NUMBERS

1 Display 24 Space 46 Heat-permeable wall

2 Adjustment unit 25 Heating element 50 Optical detection unit

3 Buffer fluid 26 Window 52 Lens

4 marker 30 Sample carrier 54 Channel

5 Target molecule 32 Rod 56 Image sensor

6 Second target molecule 34 Carrier cap 60 Particle manipulator

7 Third target molecule 40 Container 62 Magnet 10 Controller 41 Inlet 80 Lighting elements

12 Processors 42 Inlet wall f Focal length

20 Housing 43 Detection wall y Accumulation axis

21 Opening 44 Chamber z Deposition zone

22 Slot 45 Second wall

Claims

1. A detection device comprising a housing (20); a slot (22), in which a container (40) provided with a mixture containing housing (20), an organic material degrading buffer fluid (3) provided on the housing (20), a marker (4) with the appropriate oligonucleotide sequence, particle manipulator (60) in which the biomolecules released by the buffer liquid (3) in the container (40) combine with the marker (4) and one or more electrically charged target molecules (5) remain within the domain of action, and provided adjacent the slot (22) directed towards a predetermined deposition zone (z), characterized in that the container (40) is provided with a mixture, preferably containing a fluorescent marker (4), having an oligonucleotide sequence 50% identical to at least one of the genomic DNA/RNA sequence SEQID NO:1 , SEQID NO:2 and SEQID no:3, and at least one lens (52) arranged visually accessible from a front part of the slot (22) towards the deposition zone (z), and a focal length (f) adjusted to optically enlarge the focusing zone with respect to the deposition zone (z) thereof.

2. A detection device according to claim 1, wherein the marker (4) selected as a fluorescent dye is 80% identical to at least one of the genomic DNA/RNA sequence SEQID NO:1 , SEQID NO:2 and SEQID no:3.

3. A detection method according any of the preceding claims, wherein the container (40) in which oligonucleotide sequences are equipped with at least two different markers (4) applied with the selected fluorescent dye that binds to one or more respiratory viruses that are preferably 80% or 90% identical to at least one of the genomic DNA/RNA sequences SEQID NO:1, SEQID NO:2, and SEQID #3 simultaneously.

4. A detection device according to claim 1, wherein at least one image sensor (56) disposed on the back of the lens (52) in a way that ensures the focusing of the image.

5. A detection device according to any one of the preceding claims, wherein the particle manipulator (60) comprises a magnet (62) disposed facing the deposition zone (z).

6. A detection device according to claim 5, wherein the magnet (62) comprises a toroidal magnet aligned to the central deposition zone (z).

7. A detection device according to claim 6, wherein the focus of the lens (52) is located on an accumulation axis (y) passing through the toroidal center of the magnet (62).

8. A detection device according to any one of the preceding claims, wherein at least one lighting element (80) disposed in the housing (20) so as to illuminate the slot (22).

9. A detection device according to claim 8, wherein the lighting element (80) is characterized by an LED selected at a wavelength suitable for the visibility of the marker (4) to irradiate the biomolecule combined with the predetermined oligonucleotide sequence.

10. A detection device according to any of the preceding claims, wherein the marker (4) with the oligonucleotide sequence stored in the container (40) when inserted into the slot (22) comprises at least one heating element (25) adapted to the housing (20) such that it binds with the target molecule (5), catalyzing it to a catalysis temperature that increases the rate of degradation and/or binding thereof.

11. A detection device according to any one of the preceding claims, wherein a chamber (44) filled with a mixture of lysis buffer fluid (3) and at least one marker (4) having the appropriate oligonucleotide sequence, a detection wall (43) in the chamber (44) arranged at least partially translucent so as to ensure the visual accessibility from the outside and is aligned with the lens (52) when inserted into the slot (22).

12. A detection device according to claim 11 , wherein the chamber (44) comprises a heat- permeable wall (46) which is heat-conductingly engaged with the heating element (25) provided in the slot (22).

13. A detectiondevice according to claims 10-12, wherein the inlet wall, the fixing wall, the second wall and the heat-permeable wall (42, 43, 45 and 46) of the chamber (44) comprises at least one heating element (25) provided inside or outside of at least one of them.

14. A detection device according to claims 10-13, wherein cartridge (40) comprises a sealed inlet (41) that opens from the back of an outward facing inlet wall (42) when disposed on the slot (22) to allow the entrance of a carrier cap (34) located in the chamber (44) of the target molecule (5).

15. A detection device according to any of the preceding claims, wherein the fluorescent dye, as the said marker (4), that increases the visibility of the oligonucleotide marked is chosen from the group of sybr safe, sybr green, eva green, Thiazole Green, Ethidium Bromide, Propidium Iodide, dUTP-conjugated Probes, DAPI (4',6-diamidino-2- phenylindole), 7-AAD (7-aminoactinomycin D), Hoechst 33258 ( 33342, 34580), YOYO-1 /DiYO-1/TOTO-1/DiTO-1 .

16. A detection method comprising process step of filling a mixture of lysis buffer fluid (3) and marker (4) with the appropriate oligonucleotide sequence into the sealed chamber (44), wherein it also comprises the following process steps: receiving a sample carrier (30) on which the target molecule (5) will be examined from the inlet (41 ) reaching the chamber (44); exposing the buffer fluid (3) to the sample carrier (30) to release the genetic material; heating the substrate with the heating element (25), thereby increasing the rate of release time of the genetic material; entrainment of the charged target molecule (5) in the deposition zone with the particle manipulator (60) by matching the released genetic material with the marker (4) with the appropriate oligonucleotide sequence; irradiation with the lighting element (80) to reach the target molecule in the chamber (44) and optical magnification of the radiation scattered from the target molecule (5) by the lens (52) with an aligned focus to the deposition zone.

17. A detection method according to claims 16, wherein a lighting element (80) is disposed in the aforementioned chamber (44) in a way that provides illumination.

18. A detection method according to claims 16 to 17, wherein it includes the process step of digitizing the magnified reflection from the lens (52) by falling on the image sensor (56) and transferring the digital image to a display (1 ) with the help of a controller (10).

19. A detection method according to claims 16 to 18, wherein a container (40) in which oligonucleotide sequences are disposed with at least two different markers (4) applied with the selected fluorescent dye that binds to one or more respiratory viruses that are preferably 80% or 90% identical to at least one of the genomic DNA/RNA sequences SEQID NO:1 , SEQID NO:2, and SEQID #3 simultaneously.